Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

Table 2 Change in BCVA at each time point following transition to aflibercept therapy

Time point	BCVA^a (Mean ± SD)	Change from Baseline (Mean ± SD)	Change from Baseline (%)	P-value^b	95% CI
Time point	BCVA^a (Mean ± SD)	Change from Baseline (Mean ± SD)	Change from Baseline (%)	P-value^b	Lower	Upper
Baseline	0.45 ± 0.28
Month 1	0.4 ± 0.27	− 0.05 ± 0.13	6	0.01	− 0.09	-0.01
Month 3	0.41 ± 0.31	− 0.04 ± 0.16	11	0.079	− 0.08	0.01
Month 6	0.44 ± 0.35	− 0.01 ± 0.22		0.929	− 0.07	0.05
Month 12	0.47 ± 0.39	0.02 ± 0.28	7	1.00	0.06	0.1

BCVA best-corrected visual acuity, CI confidence interval
^alogMAR, log₁₀ of reciprocal of Snellen visual acuity
^b Based on hybrid linear mixed model, adjusted for multiple comparisons based on Sidak method

ISSN: 2056-9920